Korde Asawari, Jin Lei, Zhang Jian-Ge, Ramaswamy Anuradha, Hu Buqu, Kolahian Saeed, Guardela Brenda Juan, Herazo-Maya Jose, Siegfried Jill M, Stabile Laura, Pisani Margaret A, Herbst Roy S, Kaminski Naftali, Elias Jack A, Puchalski Jonathan T, Takyar Shervin S
1 Section of Pulmonary, Critical Care, and Sleep Medicine and.
2 Cleveland Clinic Cole Eye Institute and Lerner Research Institute, Cleveland, Ohio.
Am J Respir Crit Care Med. 2017 Dec 1;196(11):1443-1455. doi: 10.1164/rccm.201610-2157OC.
Vascular endothelial growth factor down-regulates microRNA-1 (miR-1) in the lung endothelium, and endothelial cells play a critical role in tumor progression and angiogenesis.
To examine the clinical significance of miR-1 in non-small cell lung cancer (NSCLC) and its specific role in tumor endothelium.
miR-1 levels were measured by Taqman assay. Endothelial cells were isolated by magnetic sorting. We used vascular endothelial cadherin promoter to create a vascular-specific miR-1 lentiviral vector and an inducible transgenic mouse. KRAS/Trp (KP) mice, lung-specific vascular endothelial growth factor transgenic mice, Lewis lung carcinoma xenografts, and primary endothelial cells were used to test the effects of miR-1.
In two cohorts of patients with NSCLC, miR-1 levels were lower in tumors than the cancer-free tissue. Tumor miR-1 levels correlated with the overall survival of patients with NSCLC. miR-1 levels were also lower in endothelial cells isolated from NSCLC tumors and tumor-bearing lungs of KP mouse model. We examined the significance of lower miR-1 levels by testing the effects of vascular-specific miR-1 overexpression. Vector-mediated delivery or transgenic overexpression of miR-1 in endothelial cells decreased tumor burden in KP mice, reduced the growth and vascularity of Lewis lung carcinoma xenografts, and decreased tracheal angiogenesis in vascular endothelial growth factor transgenic mice. In endothelial cells, miR-1 level was regulated through phosphoinositide 3-kinase and specifically controlled proliferation, de novo DNA synthesis, and ERK1/2 activation. Myeloproliferative leukemia oncogene was targeted by miR-1 in the lung endothelium and regulated tumor growth and angiogenesis.
Endothelial miR-1 is down-regulated in NSCLC tumors and controls tumor progression and angiogenesis.
血管内皮生长因子可下调肺内皮细胞中的微小RNA-1(miR-1),而内皮细胞在肿瘤进展和血管生成中起关键作用。
探讨miR-1在非小细胞肺癌(NSCLC)中的临床意义及其在肿瘤内皮细胞中的具体作用。
采用Taqman分析法检测miR-1水平。通过磁珠分选法分离内皮细胞。我们利用血管内皮钙黏蛋白启动子构建了血管特异性miR-1慢病毒载体和诱导性转基因小鼠。使用KRAS/Trp(KP)小鼠、肺特异性血管内皮生长因子转基因小鼠、Lewis肺癌异种移植瘤和原代内皮细胞来检测miR-1的作用。
在两组NSCLC患者中,肿瘤组织中的miR-1水平低于无癌组织。肿瘤miR-1水平与NSCLC患者的总生存期相关。从NSCLC肿瘤和KP小鼠模型的荷瘤肺中分离出的内皮细胞中,miR-1水平也较低。我们通过检测血管特异性miR-1过表达的作用来研究较低miR-1水平的意义。在KP小鼠中,载体介导的miR-1递送或转基因过表达可降低肿瘤负荷,减少Lewis肺癌异种移植瘤的生长和血管生成,并减少血管内皮生长因子转基因小鼠的气管血管生成。在内皮细胞中,miR-1水平通过磷酸肌醇3激酶调节,并特异性控制细胞增殖、从头DNA合成和ERK1/2激活。髓系增殖性白血病癌基因是肺内皮细胞中miR-1的靶标,可调节肿瘤生长和血管生成。
NSCLC肿瘤中内皮miR-1表达下调,可控制肿瘤进展和血管生成。